博拓生物: 浙江天册律师事务所关于杭州博拓生物科技股份有限公司2025年第二次临时股东会法律意见书

Core Viewpoint - The legal opinion letter from Zhejiang Tiance Law Firm confirms the legality and validity of the procedures and results of the second extraordinary general meeting of shareholders for Hangzhou Botao Biotechnology Co., Ltd. in 2025 [1][11]. Group 1: Meeting Procedures - The meeting was convened following the approval of the board of directors on May 19, 2025, and the notice was published on May 20, 2025, on the Shanghai Stock Exchange and other platforms [2][3]. - The meeting is scheduled for June 4, 2025, at 14:00, with specific voting times for online participation [3]. Group 2: Agenda and Voting - The agenda includes proposals to cancel the supervisory board, expand the business scope, amend the company’s articles of association, and elect new board members [2][4]. - A total of 43 shareholders (or their proxies) attended the meeting, representing 49,053,096 voting shares, which is 45.9872% of the total voting shares [5]. Group 3: Voting Results - All proposed resolutions were approved by the shareholders, with significant support for each item, such as 99.9035% approval for the proposal to amend the articles of association [6][10]. - The election of non-independent and independent directors received unanimous support, with no votes against any of the candidates [8][9].